Methods and probiotic compositions for the treatment of bone disorders

Abstract

In some aspects, methods and probiotic compositions are provided for the treatment of bone diseases such as, e.g., ostetoporosis. In some embodiments, one or more bacteria from the warm microbiota such as, e.g., Clostridialeace-assimilate, Lactobacillus, Bifidobacteriaceae, Akkermansia, and/or Parabacteroides may be administered to a subject, such as a human subject, to treat the bone disease. In some embodiments, heat may be applied to the subject to promote the development of warm microbiota to treat the bone disease.

1 - 32 . (canceled) 
     
     
         33 . A pharmaceutical or probiotic composition for delivery to the gastrointestinal system comprising a therapeutically effective amount of  Parabacteroides goldsteinii  and an excipient. 
     
     
         34 . (canceled) 
     
     
         35 . The composition of  claim 34 , wherein the  Parabacteroides goldsteinii  is heat-inactivated. 
     
     
         36 . The composition of  claim 33 , wherein the composition comprises  Lactobacillus gasseri ,  Lactobacillus reuteri , and/or heat-inactivated  Parabacteroides goldsteinii . 
     
     
         37 . The composition of  claim 33 , wherein the composition comprises extracellular vesicles from  Lactobacillus gasseri ,  Lactobacillus reuteri , and/or  Parabacteroides goldsteinii . 
     
     
         38 . (canceled) 
     
     
         39 . The composition of  claim 33 , wherein the composition comprises  Clostridialeace -assimilate  spp.  or  Lactobacillus spp . 
     
     
         40 - 43 . (canceled) 
     
     
         44 . The composition of  claim 33 , wherein the warm microbiota comprises  Bifidobacteriaceae . 
     
     
         45 . The method of  claim 44 , wherein the  Bifidobacteriaceae  is  Bifidobacterium longum . 
     
     
         46 - 47 . (canceled) 
     
     
         48 . The composition of  claim 33 , wherein the compositioncomprises frozen or dried bacteria. 
     
     
         49 . The composition of  claim 33 , wherein the composition comprises extracellular vesicles from  Parabacteroides goldsteinii  . 
     
     
         50 . The composition of  claim 33 , wherein the pharmaceutical or probiotic composition is formulated for oral, colonic, enema, orogastric, or nasogastric administration. 
     
     
         51 . The composition of  claim 33 , wherein the pharmaceutical or probiotic composition is resistant to degradation in the stomach but releases bacteria in the small intestine and/or large intestine of the subject. 
     
     
         52 . The composition of  claim 51  wherein the pharmaceutical or probiotic composition comprises an enteric coating, chitosan-alginate beads, or a hydrogel. 
     
     
         53 . The composition of  claim 52 , wherein the enteric coating is a fatty acid, a wax, a shellac, a plastic such as a phthalate, CAP, CAT, PVAP, HPMCP, or a plant fiber. 
     
     
         54 . The composition of  claim 51  wherein the pharmaceutical or probiotic composition does not comprise an enteric coating. 
     
     
         55 . The composition of  claim 33 , wherein the pharmaceutical or probiotic composition is a tablet or capsule. 
     
     
         56 - 67 . (canceled)